Jay S. Duker - 09 Feb 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
09 Feb 2025
Net transactions value
-$13,347
Form type
4
Filing time
11 Feb 2025, 18:19:11 UTC
Previous filing
07 Jan 2025
Next filing
20 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +7,000 +9.6% $0.000000 79,706 09 Feb 2025 Direct
transaction EYPT Common Stock Tax liability $13,347 -2,055 -2.6% $6.50 77,651 09 Feb 2025 Direct F1
holding EYPT Common Stock 22,500 09 Feb 2025 By Family Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -7,000 -100% $0.000000 0 09 Feb 2025 Common Stock 7,000 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
F2 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3 The restricted stock units vests in three annual installments beginning February 9, 2023.